CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seaside Therapeutics LLC announced today that the Company has entered into a collaborative research agreement with Vanderbilt University Medical Center to discover and develop small molecules targeting neurologic receptors implicated in disorders of brain development, such as Fragile X Syndrome and autism. The targets, muscarinic acetylcholine subtype 1 (M1) receptors, are known to regulate learning and memory. Research conducted by the Company suggests that inhibiting M1 receptor signaling could provide therapeutic benefit for individuals with disorders of brain development.
